Canaccord Genuity Maintains a 'Hold' on AspenBio Pharma (APPY); Q2 Preview: Trials For AppyScore Start Soon

Canaccord Genuity maintains a 'Hold' on AspenBio Pharma (NASDAQ: APPY) price target of $2.50.

Analyst, Jeffrey Frelick, said, "AspenBio Pharma does not generate meaningful sales, as it is working to commercialize its AppyScore test. For Q2/12, we expect EPS of $(0.38). We are the only firm to cover the stock and represent the consensus."

"While we believe APPY could commercialize the first Dx test for appendicitis, we remain on the sidelines."

For an analyst ratings summary and ratings history on AspenBio Pharma click here. For more ratings news on AspenBio Pharma click here.

Shares of AspenBio Pharma closed at $1.90 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics